Everything NICE has said on diagnosing and managing varicose veins in the legs in an interactive flowchart.
This guideline covers the management of Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life.
This guideline covers the management of ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Provider name: LM info Lot details Lot 2 Agent - Print Journals, Electronic Journals, Databases, Aggregated Evidence Resource Summaries
The AAC product identification process and transformative designation status
How to partner with NICE for your research.
Everything NICE has said on diagnosing and managing irritable bowel syndrome in adults in primary care in an interactive flowchart
The Accelerated Access Collaborative is a fast-track route into the NHS for “breakthrough” medicines and technologies
We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.
NICE’s new guideline is the first to offer comprehensive information on neurological conditions to help non-specialist healthcare professionals to identify people who should be referred for specialist assessment and care.
Who is the accelerated access collaborative and what do they do?
Evidence-based recommendations on durvalumab (Imfinzi) for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
Interventional Procedures Advisory Committee members
Learn how we assess the resource impact of our guidance Come to one of our free events to: see the tools available to help you plan for and implement
Everything NICE has said on diagnosing and managing acute heart failure in an interactive flowchart
Everything NICE has said on treating adults with Barrett's oesophagus who have high-grade dysplasia or early intramucosal cancer in an interactive flowchart
Everything NICE has said on investigating and managing dyspepsia and gastro-oesophageal reflux disease in an interactive flowchart
Everything NICE has said on the recognition, diagnosis and early management of sepsis in an interactive flowchart
Everything NICE has said on blood transfusions in adults, young people and children over 1 year old in an interactive flowchart
NICE guidance that could generate cost savings.
HealthTech Connect, a new online resource provided by NICE to help identify and support new health technologies as they move from inception to adoption in the UK health and care system was formally launched today (29 April).
Everything NICE has said on diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults in an interactive flowchart
Advice on LiverMultiScan for liver disease to aid local decision making
Everything NICE has said on fertility, pregnancy and childbirth in an interactive flowchart
Everything NICE has said on the care of healthy women and their babies during childbirth in an interactive flowchart
Everything NICE has said on the care of women in or at risk of preterm labour or having a planned preterm birth in an interactive flowchart
Everything NICE has said on intrapartum care for women with obstetric complications in an interactive flowchart
Everything NICE has said on recognising and managing ovarian cancer in an interactive flowchart
This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.
We provide practical support to Sustainability and Transformation Partnerships (STPs) and Integrated Care Systems (ICSs) at a local level.
We’re committed to supporting the delivery of the Five Year Forward View (5YFV).
We have dedicated teams to support local areas with implementation of our guidance, standards and advice to meet the needs of their population.
We have a continuing role in enabling the implementation of the vision and commitments set out in the Five Year Forward View (5YFV).
Everything NICE has said on diagnosing and managing lower limb peripheral arterial disease in an interactive flowchart
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults
Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart
Listed below are the highly specialised technology evaluation block scoping reports which have been submitted to the Department of Health and Social...
NICE Evidence search NICE Evidence search slide set Powerpoint Evidence type definitions Word NICE Evidence search:
Evidence-based recommendations on bisphosphonates (alendronic acid; ibandronic acid; risedronate sodium; zoledronic acid) for treating osteoporosis in adults
This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.
NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was